S&P 500   2,971.10 (+0.03%)
DOW   26,854.60 (+0.14%)
QQQ   191.51 (+0.21%)
AAPL   237.48 (+0.54%)
FB   184.11 (-0.04%)
MSFT   139.98 (+0.21%)
CGC   18.98 (-2.32%)
NVDA   185.91 (-0.04%)
BABA   171.73 (-0.71%)
GE   8.75 (-0.57%)
TSLA   255.68 (+3.14%)
T   37.44 (-0.37%)
F   8.81 (+0.34%)
NFLX   283.09 (+0.06%)
BAC   29.12 (+0.73%)
GILD   64.83 (+1.31%)
DIS   129.72 (-0.23%)
S&P 500   2,971.10 (+0.03%)
DOW   26,854.60 (+0.14%)
QQQ   191.51 (+0.21%)
AAPL   237.48 (+0.54%)
FB   184.11 (-0.04%)
MSFT   139.98 (+0.21%)
CGC   18.98 (-2.32%)
NVDA   185.91 (-0.04%)
BABA   171.73 (-0.71%)
GE   8.75 (-0.57%)
TSLA   255.68 (+3.14%)
T   37.44 (-0.37%)
F   8.81 (+0.34%)
NFLX   283.09 (+0.06%)
BAC   29.12 (+0.73%)
GILD   64.83 (+1.31%)
DIS   129.72 (-0.23%)
Log in

Glaukos Stock Price, News & Analysis (NYSE:GKOS)

$61.53
-0.16 (-0.26 %)
(As of 10/14/2019 11:38 AM ET)
Today's Range
$61.00
Now: $61.53
$61.53
50-Day Range
$57.83
MA: $64.80
$74.29
52-Week Range
$50.60
Now: $61.53
$84.65
Volume950 shs
Average Volume465,278 shs
Market Capitalization$2.24 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.69
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone949-367-9600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$181.28 million
Book Value$4.98 per share

Profitability

Net Income$-12,950,000.00

Miscellaneous

Employees437
Market Cap$2.24 billion
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable

Receive GKOS News and Ratings via Email

Sign-up to receive the latest news and ratings for GKOS and its competitors with MarketBeat's FREE daily newsletter.


Glaukos (NYSE:GKOS) Frequently Asked Questions

What is Glaukos' stock symbol?

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

How were Glaukos' earnings last quarter?

Glaukos Corp (NYSE:GKOS) issued its quarterly earnings data on Wednesday, August, 7th. The medical instruments supplier reported ($0.11) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.03. The medical instruments supplier earned $58.60 million during the quarter, compared to the consensus estimate of $56.24 million. Glaukos had a negative net margin of 5.93% and a negative return on equity of 5.77%. The firm's revenue was up 35.8% on a year-over-year basis. During the same period in the previous year, the business posted ($0.15) earnings per share. View Glaukos' Earnings History.

When is Glaukos' next earnings date?

Glaukos is scheduled to release their next quarterly earnings announcement on Wednesday, November 6th 2019. View Earnings Estimates for Glaukos.

What guidance has Glaukos issued on next quarter's earnings?

Glaukos updated its FY 2019 earnings guidance on Wednesday, August, 7th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $226-231 million, compared to the consensus revenue estimate of $230.07 million.

What price target have analysts set for GKOS?

8 equities research analysts have issued 1-year price objectives for Glaukos' stock. Their predictions range from $66.02 to $90.00. On average, they anticipate Glaukos' stock price to reach $74.57 in the next twelve months. This suggests a possible upside of 21.4% from the stock's current price. View Analyst Price Targets for Glaukos.

What is the consensus analysts' recommendation for Glaukos?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Glaukos.

What are Wall Street analysts saying about Glaukos stock?

Here are some recent quotes from research analysts about Glaukos stock:
  • 1. According to Zacks Investment Research, "Glaukos is currently progressing with the U.S. commercial rollout of its next-generation iStent inject Trabecular Micro-Bypass device. It also initiated patient enrolment of key U.S. pivotal clinical studies for iDose Travoprost and iStent Infinite. Through continued investment and a new pharmaceutical development agreement with D. Western Therapeutic Institute Glaukos expanded its pharmaceutical capabilities. A strong pipeline is indicative of brighter prospects ahead. Management is optimistic about the recent Avedro buyout. The company outperformed the industry year-to-date. With respect to quarterly results, Glaukos exited the second quarter on a tepid note. Also, Glaukos faces cutthroat competition in the Medical Devices space. Further, an overtly stringent regulatory-approval process for the iDose platform is concerning." (9/12/2019)
  • 2. BTIG Research analysts commented, "We maintain our Neutral rating on GKOS shares following a solid 1Q19 beat. Largely expected, GKOS delivered rev. of $54.0M vs. BTIG/Street est. of $49.7M/$50.2M as iStent inject conversions and OUS strength drove upside while competitive trialing was modest (below mgmt.’s initial expectations). CyPass share gains continue to buoy US results (we est. $9M-$10M/qtr.) Current business execution, market dynamics, and pricing all appear to be in-line to slightly better than originally guided with no material change to pipeline timelines. Against a ~$4M beat, mgmt. moved the lower-end of guidance up $5M (+$2.5M at the midpoint), sticking with a conservative (but optimistic) tone through the balance of the year. Mgmt. remains cautious around an increase in competitive trialing within the US combined with continued OUS challenges in the UK stemming from reimbursement cuts." (5/10/2019)

Has Glaukos been receiving favorable news coverage?

News headlines about GKOS stock have been trending negative on Monday, according to InfoTrie. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Glaukos earned a media sentiment score of -2.6 on InfoTrie's scale. They also gave media headlines about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Glaukos.

Are investors shorting Glaukos?

Glaukos saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 6,690,000 shares, an increase of 6.9% from the August 30th total of 6,260,000 shares. Based on an average daily trading volume, of 519,900 shares, the short-interest ratio is presently 12.9 days. Approximately 18.9% of the company's shares are short sold. View Glaukos' Current Options Chain.

Who are some of Glaukos' key competitors?

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include PTC Therapeutics (PTCT), Alibaba Group (BABA), Paypal (PYPL), Twilio (TWLO), NVIDIA (NVDA), Splunk (SPLK), Caterpillar (CAT), Baidu (BIDU), Coupa Software (COUP) and Boeing (BA).

Who are Glaukos' key executives?

Glaukos' management team includes the folowing people:
  • Mr. Thomas William Burns, CEO, Pres & Director (Age 58)
  • Mr. Joseph E. Gilliam, CFO & Sr. VP of Corp. Devel. (Age 43)
  • Mr. Chris M. Calcaterra, Chief Operating Officer (Age 59)
  • Mr. Richard L. Harrison, Advisor (Age 62)
  • Dr. Mory Gharib Ph.D., Co-Founder

When did Glaukos IPO?

(GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

How do I buy shares of Glaukos?

Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Glaukos' stock price today?

One share of GKOS stock can currently be purchased for approximately $61.44.

How big of a company is Glaukos?

Glaukos has a market capitalization of $2.24 billion and generates $181.28 million in revenue each year. The medical instruments supplier earns $-12,950,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. Glaukos employs 437 workers across the globe.View Additional Information About Glaukos.

What is Glaukos' official website?

The official website for Glaukos is http://www.glaukos.com/.

How can I contact Glaukos?

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected]


MarketBeat Community Rating for Glaukos (NYSE GKOS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  336 (Vote Outperform)
Underperform Votes:  249 (Vote Underperform)
Total Votes:  585
MarketBeat's community ratings are surveys of what our community members think about Glaukos and other stocks. Vote "Outperform" if you believe GKOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GKOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Featured Article: Elliott Wave Theory

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel